comparison of glp 1 agonists TrimRX Frontiers | Exploring the multifaceted
Description
doi: 10.4103/2230-8210.111625
Our specialists carefully monitor each patient to ensure safe use and adjust treatment as needed
This confirmed what obesity researchers have argued for years: obesity is a chronic condition that requires ongoing treatment, just like hypertension or diabetes
Questions regarding the cardiovascular safety of drugs prescribed for T2DM arose as individuals treated with sulfonylureas and insulin showed an increased incidence of major adverse cardiovascular events (MACEs: death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) [18, 19]
